Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LM-302 in CLDN18.2-positive Advanced Gastric or GEJ Adenocarcinoma
NCT06351020Phase 3Active, not recruiting
- Sponsor
- LaNova Medicines
- Start
- Jun 2024
- Primary completion
- Nov 2026
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of tpx-4589 in gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, sponsored by LaNova Medicines. Started Jun 2024; status: active, not recruiting.
02
Drugs
tpx-4589
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT06351020.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06351020.